:: Volume 25, Issue 2 (7-2017) ::
Journal of Ilam University of Medical Sciences 2017, 25(2): 166-172 Back to browse issues page
Evaluating the Prevalence of Plasminogen Activator Inhibitor-1 Gene Polymorphism in Patients with Thyroid Tumors from North West of Iran
Mahdieh Younesi1 , Mohammadali Hosseinpour Feizi * 2, Nasser Pouladi3
1- Dept of Animal Biology, Faculty of Natural Sciences, Tabriz University,Tabriz, Iran
2- Dept of Animal Biology, Faculty of Natural Sciences, Tabriz University,Tabriz, Iran , pourfeizi@eastp.ir
3- Dept of Biology, Faculty of Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran
Abstract:   (4611 Views)

Introduction: Association of PAI-1 polymorphisms with the increased risk of various malignancies has been shown in numerous studies. Therefore, the aim of the current study is to evaluate the prevalence of PAI-1 4G/5G polymorphism in patients with thyroid tumors from North West of Iran.

Materials & methods: Ninety patients with thyroid tumors and 180 healthy controls were selected from North West of Iran. DNA was extracted from peripheral blood samples and 4G/5G polymorphism of the PAI-1 gene was evaluated by polymerase chain reaction using specific primers.

Findings: Genotype distribution between patients was (4G/4G=13.33%, 4G/5G=63.33% and 5G/5G=23.33%) and controls (4G/4G=17.22%, 4G/5G=67.22% and 5G/5G=15.55%). Additionally, the frequencies of the 4G and 5G alleles between patients were (45% and 55%) and control group (50.83% and 49.16%).

Discussion & conclusions: Results indicate that the genotypic and allelic frequencies of PAI-1 4G/5G polymorphism showed no significant difference between patients with thyroid tumors and control individuals in this cohort.

Keywords: Polymorphism, Plasminogen activation system, Thyroid tumors
Full-Text [PDF 353 kb]   (1643 Downloads)    
Type of Study: Research |
Received: 2015/12/16 | Accepted: 2016/02/14 | Published: 2017/07/18



XML   Persian Abstract   Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 25, Issue 2 (7-2017) Back to browse issues page